CANCER TREATMENT REGIMENS
Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced healthcare team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. These regimens are only provided to supplement the latest treatment strategies.
These Guidelines are a work in progress that may be refined as often as new significant data becomes available. The NCCN Guidelines® are a consensus statement of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.
Sign Up for Free e-newsletters
Cancer Therapy Advisor Articles
- CD151—A Striking Marker for Cancer Therapy
- Addition of Levetiracetam May Improve Survival for Glioblastoma
- Malignant Gastric Outlet Obstruction
- Azacitadine May Be Safe, Effective for Older Patients with Acute Myeloid Leukemia
- Study Suggests Renal Cell Carcinoma Reprograms its Metabolism to Evade Immune System
- Vitamin D Levels and Risk for Pancreatic Cancer
- New Screening Method May Identify Twice As Many Women with Ovarian Cancer
- Head and Neck Cancers Treatment Regimens
- Nicotinamide Safe, Effective for Non-Melanoma Skin Cancer Prevention in High-Risk Patients
- Do Patients with Locally Advanced Rectal Cancer Benefit from Adjuvant Chemotherapy?
- Dexrazoxane Not Associated with Late Mortality in Pediatric Patients
- First-Line Bevacizumab for Glioblastoma Not Likely To Be Cost-Effective
- Nivolumab Appears Safe, Effective in Wild-Type, Mutant BRAF Melanoma
- Enoxaparin Efficacious, Feasible for Prevention of VTE in Advanced Pancreatic Cancer
- Identifying Genetic Variations Associated with Risk of Prostate Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|